COMMUNIQUÉS West-GlobeNewswire

Exagen to Announce First Quarter 2024 Results on May 13, 2024
30/04/2024
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on [...]
Merit Medical Reports Results for First Quarter Ended March 31, 2024
30/04/2024
Q1 2024 reported revenue of $323.5 million, up 8.7% compared to Q1 2023 Q1 2024 constant currency revenue* up 9.3% compared to Q1 2023 Q1 2024 constant currency revenue, organic* up 7.0% compared to Q1 2023 Q1 2024 GAAP [...]
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
30/04/2024
Management will also participate in four upcoming investor healthcare conferences SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision [...]
Stryker reports first quarter 2024 operating results
30/04/2024
Portage, Michigan, April 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2024: First Quarter Results Reported net sales increased 9.7% to $5.2 billion Organic net [...]
Bionano to Present at the RBC Capital Markets 2024 Global Healthcare Conference
30/04/2024
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the RBC Capital Markets 2024 [...]
Predictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu Vaccine
30/04/2024
PITTSBURGH, April 30, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announces a collaboration with FluGen to bring a first-of-its-kind intranasal [...]
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
30/04/2024
-- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in May -- WATERTOWN, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company [...]
MIMEDX Announces First Quarter 2024 Operating and Financial Results
30/04/2024
Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call [...]
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
30/04/2024
Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company’s Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) held [...]
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
30/04/2024
NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today released its 2023 Corporate Responsibility Report, which showcases the company’s efforts to transform the lives of [...]
Better Choice is Encouraged by the Potential DEA Reclassification of Marijuana
30/04/2024
Bona Vida CBD Dog and Cat treats remains a wholly-owned subsidiary of Better Choice NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet health and [...]
BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately
30/04/2024
Mr. Amato will also serve on the Company’s Board of Directors Westport, CT, April 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "the Company"), a medical technology Company [...]
XORTX Reprices Warrants Issued in Connection with Previous Private Placements
30/04/2024
CALGARY, Alberta, April 30, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on [...]
Crossject annonce le lancement d’une augmentation de capital
30/04/2024
Crossject annonce le lancement d’une augmentation de capital avec maintien du droit préférentiel de souscription d’un montant d’environ 8 millions d’euros pour renforcer ses sources de financement de l’enregistrement de [...]
Synaptive Medical Showcases First Clinical Use of Near-Infrared Fluorescence Visualization on Robotic Exoscope at the American Association of Neurological Surgeons Annual Meeting
30/04/2024
Surgeons report that Modus X is the ultimate visualization tool for all levels of complex microsurgery Synaptive Medical will demonstrate its recent FDA cleared near-infrared fluorescence that is now available on its [...]
AB Science announces a slight delay in the publication of its 2023 annual financial report
30/04/2024
PRESS RELEASE AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2023 ANNUAL FINANCIAL REPORT THE COMPANY WILL PUBLISH ITS 2023 ANNUAL FINANCIAL REPORT NO LATER THAN 15 MAY 2024 Paris, April 30 2024, 6.30pm [...]
AB Science annonce un léger décalage de la publication de son rapport financier annuel 2023
30/04/2024
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE UN LEGER DECALAGE DE LA PUBLICATION DE SON RAPPORT FINANCIER ANNUEL 2023 LA SOCIETE PUBLIERA SON RAPPORT FINANCIER ANNUEL 2023 AU PLUS TARD LE 15 MAI 2024 Paris, 30 avril 2024, [...]
EssilorLuxottica: EssilorLuxottica 2024 Annual Shareholders’ Meeting, starting a new chapter of the Company’s history
30/04/2024
EssilorLuxottica 2024 Annual Shareholders’ Meeting, starting a new chapter of the Company’s history All resolutions proposed by the Board of Directors adopted Dividend of Euro 3.95 per share, with option for payment in [...]
EssilorLuxottica: Assemblée générale 2024 d’EssilorLuxottica, un nouveau chapitre de l’histoire du Groupe s’ouvre
30/04/2024
Assemblée générale 2024 d’EssilorLuxottica, un nouveau chapitre de l’histoire du Groupe s’ouvre Toutes les résolutions proposées par le Conseil d’administration adoptées Dividende de 3,95 € par action, avec possibilité [...]

Pages